infographic: the bottleneck in patient recruitment
DESCRIPTION
The growth rate of compounds in development far exceeds population growth and the number of investigators remains mostly flat. Because of this, patient recruitment for clinical trials functions as a bottleneck in the process. The industry has to increase its focus on Patient Recruitment. Copyright Industry Standard Research.TRANSCRIPT
Priorities
Viewpoints
Implications
Clinical trials involve five main groups, each with di�erent views and motivations. Here’s what they’re saying about clinical trials:
Patients SponsorsInvestigatorsSite Coordinators FDA
Faster patient recruitment leads to fewer delays in clinical trials, which means getting drugs on the shelf quicker. So why do only 2% of sponsors rank patient recruitment strategy as the most important when selecting a service provider?
47%
of clinical development decision-makers would
prefer a 30% lower clinical trial cost than
10% faster patient recruitment
Cost of an average Phase II Study.
Length of an average Phase II Study.
The growth rate of compounds in
development far exceeds population
growth and the number of investigators
remains mostly flat. Because of this, patient
recruitment for clinical trials functions as a
bottleneck in the process. The industry has
to increase its focus on Patient Recruitment.
30% savings of an average Phase II Study.
$1,111/day
Revenue generated per day by The 100th best selling drug in 3Q2012 (Stelara)
$1,885,000/day
$1.5-$2M 18-24 months
What would 30% lower costs mean?
What would 10% faster patient recruitment mean?
vs.
69% 233%70%76%
said they have not participated in clinical
trials because they were not made aware
of any trials.
said the hardest part of patient recruitment is
finding the right investigators.
said they are involved in the right amount, or too
many clinical trials.
said that inclusion/exclusion criteria have the single
biggest impact on patient recruitment success.
increase in patients required per NDA from
1500 in the 1970s to more than 5000 today.
of sites in a given trial fail to enroll a single patient
of sites in a given trial under-enroll
of sites in a given trial meet their enrollment targets
of sites in a given trial exceed their targets
11% 37% 39% 13%
The patient recruitment methods with the highest value, tend to be the more traditional methods:
Dr. ReferralPoster in Doctor’s O�ceLocal Newspaper
Mail from Doctor Custom Website
A�nity GroupsRadio
sources: clinicaltrials.gov, Tufts, ISR Reports Data Copyright 2013 Industry Standard Research | ISRreports.com | [email protected]
28%
Patient Recruitmentin